Adagene (ADAG) Stock Overview
A clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
ADAG Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Adagene Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.85 |
| 52 Week High | US$3.16 |
| 52 Week Low | US$1.30 |
| Beta | 0.71 |
| 1 Month Change | -2.63% |
| 3 Month Change | -8.42% |
| 1 Year Change | -4.64% |
| 3 Year Change | 60.87% |
| 5 Year Change | n/a |
| Change since IPO | -93.83% |
Recent News & Updates
Recent updates
Adagene Inc. (NASDAQ:ADAG) Surges 26% Yet Its Low P/S Is No Reason For Excitement
Oct 10
The Consensus EPS Estimates For Adagene Inc. (NASDAQ:ADAG) Just Fell Dramatically
Oct 05Adagene ADR GAAP EPS of -$0.87 misses by $0.45, revenue of $3.93M misses by $9.82M
Aug 30Micro-cap Adagene surges after hours on $10M share buyback
Jun 29Shareholder Returns
| ADAG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.5% | 2.6% | 2.6% |
| 1Y | -4.6% | 25.9% | 14.2% |
Return vs Industry: ADAG underperformed the US Biotechs industry which returned 25.9% over the past year.
Return vs Market: ADAG underperformed the US Market which returned 14.2% over the past year.
Price Volatility
| ADAG volatility | |
|---|---|
| ADAG Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ADAG's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ADAG's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 138 | Peizhi Luo | www.adagene.com |
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development.
Adagene Inc. Fundamentals Summary
| ADAG fundamental statistics | |
|---|---|
| Market cap | US$87.19m |
| Earnings (TTM) | -US$29.89m |
| Revenue (TTM) | US$103.20k |
Is ADAG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADAG income statement (TTM) | |
|---|---|
| Revenue | US$103.20k |
| Cost of Revenue | US$0 |
| Gross Profit | US$103.20k |
| Other Expenses | US$29.99m |
| Earnings | -US$29.89m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.63 |
| Gross Margin | 100.00% |
| Net Profit Margin | -28,961.70% |
| Debt/Equity Ratio | 17.5% |
How did ADAG perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/24 01:08 |
| End of Day Share Price | 2025/12/24 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Adagene Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ziyi Chen | Goldman Sachs |
| Paul Jeng | Guggenheim Securities, LLC |
| Yu He | H.C. Wainwright & Co. |